Cytokinetics updates Phase 2b tirasemtiv program
Emergent BioSolutions presents positive interim phase 2 data evaluating otlertuzumab (TRU-016) in combination with bendamustine in relapsed CLL
Read the buzz on Covidien’s purchase of Given Imaging
For daily banking news and anonymous message boards, check out the new site cafebanking.com.
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Agilent | 3 | 22 | 633 % |
| Emergent BioSolutions | 1 | 7 | 600 % |
| Coastal Pharmaceuticals | 1 | 4 | 300 % |
| Dragon Pharmaceutical | 1 | 4 | 300 % |
| Charles River Laboratories | 20 | 64 | 220 % |
| Alcon | 4 | 12 | 200 % |
| Genentech | 3 | 9 | 200 % |
| Circadian Technologies | 1 | 3 | 200 % |
| Cordis | 1 | 3 | 200 % |
| Covidien | 2 | 6 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Acura Pharmaceuticals | 4 | 60 | 1400 % |
| United Therapeutics | 11 | 99 | 800 % |
| Syneron Medical | 1 | 8 | 700 % |
| Medivir | 5 | 33 | 560 % |
| Alkermes | 8 | 50 | 525 % |
| Agenus | 1 | 6 | 500 % |
| Acorda Therapeutics | 1 | 6 | 500 % |
| SCM Pharma | 1 | 6 | 500 % |
| Emergent BioSolutions | 7 | 38 | 443 % |
| Durect Corporation | 1 | 5 | 400 % |